Valbiotis SA (FR:ALVAL) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Valbiotis, a French research lab focusing on dietary supplements for metabolic disorders, reported on their liquidity contract with Portzamparc, showing an inventory of 31,296 shares and 25,655.71 euros as of June 30, 2024. This reflects a dynamic trade period with 67,938 shares bought and 51,991 sold in the first half of 2024. The company emphasizes its commitment to innovation in health nutrition, aiming to reduce the risk of cardiovascular diseases.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.